A prospective, randomised, open label phase II study of active specific immunotherapy with racotumomab versus support treatment in patients with advanced non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2014
At a glance
- Drugs Racotumomab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Elea
- 09 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Nov 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
- 09 Jun 2010 New trial record